NCT07158918招募中1 期
A Multicenter, Open-label, Phase 1b/2 Trial of ABL103, a Bispecific Antibody of B7-H4 and 4-1BB, in Combination With Pembrolizumab With/Without Taxane in Subjects With Selected, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 65
- 试验地点
- 6
- 主要终点
- Incidence of Treatment-Emergent Adverse Events (TEAEs), Treatment-Related AEs, Serious AEs (SAEs), and Infusion-Related Reactions (IRRs)
研究概览
简要总结
This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must understand and be willing to provide informed consent and be able to comply with the study procedures and restrictions.
- •Subjects must be ≥18 years of age on the day of signing the informed consent form (ICF).
- •Subject must have a histologically or cytologically confirmed locally advanced unresectable, or metastatic solid tumor.
- •Subject must be relapsed or be refractory to available standard therapy or they must be intolerant of available standard therapy.
- •Subject must meet Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 assessed 7 days before the first administration of the study drug.
- •Subjects must be recovered from AEs from prior therapy to Grade 1 or the baseline grade more than 14 days prior to the first administration of the study drug, except alopecia or Grade 2 toxicities that are deemed stable or irreversible (e.g., peripheral neuropathy)
- •Subjects who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Subject with endocrine-related AEs who are adequately treated with hormone replacement or subjects who have ≤Grade 2 neuropathy are eligible.
- •Subjects must have adequate hematologic, renal, hepatic, and thyroid function at screening and within 7 days prior to the first administration of study drug.
- •Female subjects who are not surgically sterile or postmenopausal must agree to use a highly effective method of birth control (2 methods strongly recommended) during the study and for 6 months following the last dose of ABL103/pembrolizumab.
- •Female subjects of childbearing potential must have a negative serum pregnancy test at screening and within 7 days prior to Cycle 1 Day 1 (C1D1).
- •Male subjects with female partner(s) of childbearing potential must agree to use contraception and and must not donate sperm during the treatment period with ABL103 and taxane and for at least 6 months after the final administration of ABL103 and taxane.
- •Male subjects with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom throughout the study period, and for at least 6 months after the final administration of ABL103 and taxane, and during the partner's pregnancy or breastfeeding period. When using a male condom, the partner must also use an additional method of contraception acceptable for female subjects.
排除标准
- •Subject has received prior anticancer monoclonal antibody treatment or investigational therapy (agent or device) for which the pharmacologic or toxicity profile is not expected to have resolved prior to the first administration of the study drug. A minimum of 28 days is generally recommended for agents with known delayed toxicities or prolonged biological activity, unless otherwise justified.
- •Subject has received prior radiotherapy within 2 weeks of the first administration of study drug, or has radiation-related toxicities, requiring corticosteroids.
- •Subject has received any prior immunotherapy and was discontinued from the treatment due to a Grade 3 or higher irAE (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis.
- •Subject has received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of study treatment.
- •Subject has risk factors for bowel obstruction or bowel perforation, including, but not limited to a history of acute diverticulitis, intra-abdominal abscess, and abdominal carcinomatosis. Subjects with ovarian cancer with a history of abdominal carcinomatosis can be enrolled.
研究组 & 干预措施
ABL103 (DL2) + pembrolizumab + taxane
Experimental
Safety Lead-in Part 2
干预措施: ABL103 (Drug)
ABL103 (DL2-1) + pembrolizumab + taxane
Experimental
Safety Lead-in Part 2
干预措施: Taxane (Drug)
ABL103 (DL1) + pembrolizumab
Experimental
Safety Lead-in Part 1
干预措施: ABL103 (Drug)
ABL103 (DL1) + pembrolizumab
Experimental
Safety Lead-in Part 1
干预措施: KEYTRUDA® (pembrolizumab) (Drug)
ABL103 (DL2-1) + pembrolizumab + taxane
Experimental
Safety Lead-in Part 2
干预措施: ABL103 (Drug)
ABL103 (DL2-1) + pembrolizumab + taxane
Experimental
Safety Lead-in Part 2
干预措施: KEYTRUDA® (pembrolizumab) (Drug)
ABL103 (DL2) + pembrolizumab + taxane
Experimental
Safety Lead-in Part 2
干预措施: KEYTRUDA® (pembrolizumab) (Drug)
ABL103 (DL2) + pembrolizumab + taxane
Experimental
Safety Lead-in Part 2
干预措施: Taxane (Drug)
Group 1) ABL103 + pembrolizumab + taxane
Experimental
Dose-expansion Part
干预措施: ABL103 (Drug)
Group 1) ABL103 + pembrolizumab + taxane
Experimental
Dose-expansion Part
干预措施: KEYTRUDA® (pembrolizumab) (Drug)
Group 1) ABL103 + pembrolizumab + taxane
Experimental
Dose-expansion Part
干预措施: Taxane (Drug)
Group 2) ABL103 + pembrolizumab + taxane
Experimental
Dose-expansion Part
干预措施: ABL103 (Drug)
Group 2) ABL103 + pembrolizumab + taxane
Experimental
Dose-expansion Part
干预措施: KEYTRUDA® (pembrolizumab) (Drug)
Group 2) ABL103 + pembrolizumab + taxane
Experimental
Dose-expansion Part
干预措施: Taxane (Drug)
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events (TEAEs), Treatment-Related AEs, Serious AEs (SAEs), and Infusion-Related Reactions (IRRs)
时间窗: From baseline through study completion, an average of 12 months
Recommended Dose for Expansion (RDE) Determination
时间窗: From baseline through study completion, an average of 12 months
Objective Response Rate (ORR)
时间窗: Up to approximately 30 months
Disease Control Rate (DCR)
时间窗: Up to approximately 30 months
Incidence of Dose-Limiting Toxicities (DLTs)
时间窗: Day 1 to Day 21 (Safety Lead-in Part 1) and Day 1 to Day 28 (Safety Lead-in Part 2)
次要结局
- Preliminary Objective Response Rate (ORR)(Up to approximately 30 months)
- Preliminary Disease Control Rate (DCR)(Up to approximately 30 months)
- Incidence of Anti-Drug Antibodies (ADA)(From baseline through study completion, an average of 12 months)
研究者
研究点 (6)
Loading locations...
相似试验
Unknown
1 期
Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer PatientsMetastatic Colorectal CancerNCT03626922NSABP Foundation Inc33
已完成
3 期
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)Prostatic NeoplasmsNCT03834493Merck Sharp & Dohme LLC1,244
终止
3 期
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China ExtensionProstatic NeoplasmsNCT04907227Merck Sharp & Dohme LLC81
已完成
3 期
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)Prostatic NeoplasmsNCT03834506Merck Sharp & Dohme LLC1,030
进行中（未招募）
早期 1 期
Pembrolizumab Plus Y90 Radioembolization in HCC SubjectsHepatocellular CarcinomaNCT03099564Ashwin Somasundaram30